Stock vs Stock Comparison

Amneal Pharmaceuticals, Inc. vs Abbott Laboratories

ABT wins the Tale of the Tape 5–4.

AMRX
ABT$86.99

🏆 Tale of the Tape

45
AMRXABT
2.4%Profitability (Net Margin)14.7%
57.7xValuation (P/E)24.0x
10.7%Efficiency (ROIC)10.1%
7/9Health (Piotroski F)5/9
1.9Safety (Altman Z)4.9
8.1%Growth (Rev YoY)5.7%
Risk (Sharpe 1Y)-1.05
-52.57xBalance Sheet (D/E)0.64x
3.56%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricAMRXABT
Market Cap$4.0B$149.1B
P/E Ratio57.7x24.0x
Forward P/E10.8x14.1x
P/B-56.40x2.86x
Dividend Yield2.94%
Beta1.300.65

Quantitative Metrics

MetricAMRXABT
DCF Fair Value$0.90$57.20
DCF Upside-43.2%
Piotroski F7/95/9
Altman Z1.944.87
Beneish M-2.74-2.53
FCF Yield3.56%4.21%
Net Debt/EBITDA3.8x0.1x
ROIC10.7%10.1%
WACC9.3%9.4%
ROIC – WACC1.4pp0.7pp
Gross Margin36.9%56.4%
Net Margin2.4%14.7%
Rev Growth YoY8.1%5.7%
Sharpe (1Y)-1.05
Max Drawdown 3Y
FCF Payout Ratio56%

AMRX Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

AMRX found in:

XPH1.78%
SLYG0.15%
SPSM0.13%
SLYV0.10%
VHT0.03%
SPTM0.00%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

AMRX vs ABT: Head-to-Head Analysis

Amneal Pharmaceuticals, Inc. (AMRX) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABT leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, AMRX generates a return on invested capital (ROIC) of 10.7% compared to ABT's 10.1%. This suggests AMRX is more effective at deploying capital to generate shareholder returns.

AMRX appears in 6 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, AMRX or ABT?

Our quantitative analysis compares AMRX and ABT across nine fundamental dimensions. ABT wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are AMRX and ABT correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.